{"classes":[{"categories":[{"measurements":[{"comment":"Data not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"55.2","upperLimit":"NA","value":"61.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"}],"units":"Participants"}],"title":"CLL/SLL"},{"categories":[{"measurements":[{"comment":"Data not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"48.9","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"}],"units":"Participants"}],"title":"WM"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.4","upperLimit":"45.5","value":"27.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"title":"MCL"},{"categories":[{"measurements":[{"comment":"Data not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"17.1","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"MZL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.7","upperLimit":"22.9","value":"10.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"title":"FL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"5.6","value":"4.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"DLBCL"},{"categories":[{"measurements":[{"comment":"Data not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"2.8","upperLimit":"NA","value":"17.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"RT"},{"categories":[{"measurements":[{"comment":"Data not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"28.7","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"HCL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"378"}],"units":"Participants"}],"description":"PFS is defined as the time from the first dose date of study drug to the date of the earliest occurrence of progressive disease or death due to any cause, whichever occurs first. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).","dispersionType":"95% Confidence Interval","groups":[{"description":"The dose regimens from Part 1 (40 mg, 80 mg, 160 mg QD, 160 mg BID and 320 mg QD) and Part 2 (160 mg BID and 320 mg QD) were evaluated in different disease types. Efficacy evaluations are reported by disease type for Parts 1 and 2 combined, as pre-specified in the statistical analysis plan.","id":"OG000","title":"Part 1 and Part 2: Overall"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Set consists of all participants who received at least one dose of zanubrutinib; for WM, participants also must have a baseline IgM (or M-protein) ≥ 5 g/L and no prior exposure to a BTK inhibitor.","reportingStatus":"POSTED","timeFrame":"Up to 6 years and 7 months","title":"Part 1 and Part 2: Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}